➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Express Scripts
Medtronic
McKinsey
McKesson

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRIAZOLAM

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Triazolam

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00671632 ↗ Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse Completed Takeda Phase 2 2003-06-01 The purpose of this study is to determine the relative abuse potential of ramelteon, once daily (QD), compared to triazolam in subjects with a history of drug abuse.
NCT00695630 ↗ Flumazenil Reversal of Oral Triazolam Completed National Institutes of Health (NIH) Phase 1/Phase 2 2006-09-01 An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes).
NCT00695630 ↗ Flumazenil Reversal of Oral Triazolam Completed University of Washington Phase 1/Phase 2 2006-09-01 An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Triazolam

Condition Name

Condition Name for Triazolam
Intervention Trials
Healthy 3
Dental Anxiety 2
Anxiety 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Triazolam
Intervention Trials
Dissociative Disorders 1
Vitreous Detachment 1
Hepatitis C 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Triazolam

Trials by Country

Trials by Country for Triazolam
Location Trials
United States 8
Lebanon 1
Switzerland 1
United Kingdom 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Triazolam
Location Trials
Massachusetts 1
Texas 1
Georgia 1
Florida 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Triazolam

Clinical Trial Phase

Clinical Trial Phase for Triazolam
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Triazolam
Clinical Trial Phase Trials
Completed 9
Not yet recruiting 4
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Triazolam

Sponsor Name

Sponsor Name for Triazolam
Sponsor Trials
Pfizer 3
Vejle Hospital 1
University of Liverpool 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Triazolam
Sponsor Trials
Other 22
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
McKesson
Boehringer Ingelheim
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.